Microbix Biosystems is a biotechnology company commercializing novel technologies for influenza vaccine manufacturing and livestock semen sexing, in addition to a core business of virology products.
Earlier, Baron has worked with GlaxoSmithKline and Novartis in the recent past and Martin brings 30 years of worldwide vaccine and pharma management experience to the China venture.
Baron and Martin have already started recruiting an experienced team of international vaccine and pharmaceutical managers to the Hunan/Microbix Joint Venture.
Microbix CEO William Gastle said they combined an outstanding management team, with strong financial resources and the vaccine production technology to build the most advanced vaccine facility in the world.